Clinical trial • Phase I • Neurology|Rare Disease
Lu AH70212 for Narcolepsy
Phase I trial of Lu AH70212 for Narcolepsy. 104 participants.
Overview
- Trial Therapeutic Area
- Neurology|Rare Disease
- Trial Disease
- Narcolepsy
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 15-01-2026
- First CTIS Authorization Date
- 09-02-2026
Trial design
Phase I trial across 1 site in France.
- Target Sample Size
- 104
Eligibility
Recruits 104 No vulnerable population selected; no consent or assent handling described..
- Vulnerable Population
- No vulnerable population selected; no consent or assent handling described.
Recruitment
- Planned Sample Size
- 104
- Recruitment Window Months
- 13
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 104
France
- Earliest CTIS Part Ii Submission Date
- 14-01-2026
- Latest Decision Or Authorization Date
- 05-05-2026
- Processing Time Days
- 111
- Number Of Sites
- 1
- Number Of Participants
- 104
Sites
- Site Name
- Biotrial
- Department Name
- Unité clinique
- Contact Person Name
- Hakim Charfi
- Contact Person Email
- Hakim.Charfi@biotrial.com
Sponsor
Primary sponsor
- Full Name
- H. Lundbeck A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- Lu AH70212
- Investigational Product Name
- Lu AH69593
Related trials
Other published trials that may interest you.